In a completed trial by Jabbour et al., concurrent PD-1 treatment with chemoradiotherapy was well tolerated with encouraging PFS of 69.7% at 12 months, however, with potentially an increased risk of pneumonitis using concurrent PD-1 checkpoint blockade (5). The gene discussed is PDCD1; the disease is pneumonitis.